Skip to main content
CAPE – A Non-Interventional Clinical Study to Evaluate Long-Term Safety and Effectiveness of HUMIRA (Adalimumab) in Pediatric Patients With Moderately to Severely Active Crohn's Disease (CD)
- Aim: This is a registry study to evaluate the long-term safety and effectiveness of adalimumab in pediatric patients with moderately to severely active CD who are treated as recommended in the product label. Requires quality of life questionnaire.
- Eligibility: Children between the ages of 6 and 17 years with moderate to severe CD on Humira, 6MP, azathioprine or methotrexate.
- Benefits: Stipend for subjects
- More information: https://clinicaltrials.gov/ct2/show/NCT02130362